Insulet Co. (NASDAQ:PODD) Stake Lessened by Silvant Capital Management LLC

Silvant Capital Management LLC lessened its holdings in Insulet Co. (NASDAQ:PODD) by 0.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 12,769 shares of the medical instruments supplier’s stock after selling 90 shares during the quarter. Silvant Capital Management LLC’s holdings in Insulet were worth $2,972,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Wedmont Private Capital increased its stake in Insulet by 3.5% in the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock valued at $326,000 after buying an additional 48 shares during the period. Blue Trust Inc. increased its stake in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Insulet by 1.1% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock worth $1,264,000 after acquiring an additional 66 shares in the last quarter. Greenleaf Trust boosted its position in Insulet by 4.2% during the third quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier’s stock valued at $415,000 after purchasing an additional 72 shares during the last quarter. Finally, UMB Bank n.a. boosted its position in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter.

Insulet Trading Up 1.8 %

Insulet stock opened at $235.61 on Friday. The business’s 50-day simple moving average is $227.10 and its 200-day simple moving average is $201.20. Insulet Co. has a 52 week low of $137.68 and a 52 week high of $243.98. The firm has a market capitalization of $16.52 billion, a PE ratio of 42.84, a PEG ratio of 4.30 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. During the same quarter last year, the firm earned $0.38 earnings per share. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. Equities research analysts forecast that Insulet Co. will post 3.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of recent research reports. BTIG Research raised their price target on Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Barclays raised their price objective on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. UBS Group boosted their target price on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Canaccord Genuity Group raised their price target on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Finally, Piper Sandler upped their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $242.29.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.